Navigation Links
Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.
Date:11/13/2008

Sigma-Aldrich to Carry Key Products for Regenerative Medicine and Stem Cell

Biology Research

ST. LOUIS, Nov. 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced a distribution agreement with AlphaGenix, Inc., a leading developer and manufacturer of products for basic and clinical life science research. Sigma-Aldrich will now be the exclusive supplier of AlphaGenix-developed antibodies and research tools for the fields of regenerative medicine and stem cell biology. This partnership will further augment Sigma-Aldrich's growing product portfolio of life science tools for stem cell research (http://www.sigma-aldrich.com/stemcell).

The new product offerings include antibodies to stem cell markers; tools for 3-D stem cell culture systems, such as MaxGel(TM), a human derived extracellular Matrix (ECM) and its components; and HydroMatrix(TM), a synthetic peptide scaffold that offers the precision and control of a synthesized matrix with the natural 3-D architecture of a highly crosslinked peptide hydrogel.

Over the past decade, researchers have developed a number of enhanced 3-D cell culture systems that better resemble in vivo systems. Both MaxGel and HydroMatrix promote cell growth and migration and have been shown to support the proliferation and enhance function of many cell types, including neural stem cells, neurons, glia, astrocytes, fibroblasts, and keratinocytes.

"It is increasingly important to design cell culture assays that closely mimic the behavior of cells in living tissues," said Carl Schrott, Director of Marketing for Regenerative Medicine and Research Cell Culture at Sigma-Aldrich. "Through this partnership, we will offer our customers new tools to grow stem cells that resemble their in vivo counterparts, and the high-quality antibodies needed to study them."

To access Sigma-Aldrich's extensive portfolio of reagents and kits for life science researchers, visit http://www.sigma-aldrich.com/lifescience

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

About AlphaGenix, Inc.: AlphaGenix is a life science company that develops novel products and technologies for basic and clinical research with a particular emphasis on stem cell markers, biomaterials and regenerative medicine. The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models with a focus on neurological disease. For more information on AlphaGenix and its products, which are sold worldwide, visit our website at http://www.alphagenix.com

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
2. Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
3. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
4. Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend
5. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
10. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
11. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: